Compare Abbott Laboratories (ABT) vs Constellation Energy Corporation (CEG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Constellation Energy Corporation — how do they compare? Abbott Laboratories trades at $95.21 (market cap $166.94B), while Constellation Energy Corporation trades at $240.78 (market cap $85.60B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | CEG | |
|---|---|---|
Market Cap | $166.94B | $85.60B |
Sector | Health | Energy |
52-Week High | $136.62 | $403.95 |
52-Week Low | $82.57 | $236.50 |
Enterprise Value | $193.69B | $107.27B |
Dividend Yield | 2.63% | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
CEG trades at $245.87, up 2.77% today, with a bearish technical signal but strong fundamentals. Recent earnings beat expectations in two of the last three quarters. The company benefits from rising AI-driven electricity demand and long-term nuclear power purchase agreements with major clients like Walmart and Meta. Cash flow from operations remains robust at $4.24 billion for 2025, supporting dividend payments and growth investments.
The stock presents a compelling opportunity with a consensus price target of $343.50, implying significant upside. However, risks include high capital expenditures in 2026 leading to negative net cash flow and competitive pressures in the utilities sector. Analyst sentiment is strongly bullish with 70% buy ratings, but technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Constellation Energy Corporation
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →
